| Literature DB >> 33489010 |
Andreas Kronbichler1,2, Ewan M Harrison2,3,4, Josef Wagner5.
Abstract
The human nasal microbiome is characterized by biodiversity and undergoes changes during the span of life. In granulomatosis with polyangiitis (GPA), the persistent nasal colonization by Staphylococcus aureus (S. aureus) assessed by culture-based detection methods has been associated with increased relapse frequency. Different research groups have characterized the nasal microbiome in patients with GPA and found that patients have a distinct nasal microbiome compared to controls, but the reported results between studies differed. In order to increase comparability, there is a need to standardize patient selection, sample preparation, and analytical methodology; particularly as low biomass samples like those obtained by nasal swabbing are impacted by reagent contamination. Optimization in obtaining a sample and processing with the inclusion of critical controls is needed for consistent comparative studies. Ongoing studies will analyze the nasal microbiome in GPA in a longitudinal way and the results will inform whether or not targeted antimicrobial management in a clinical trial should be pursued or not. This review focuses on the proposed role of S. aureus in GPA, the (healthy) nasal microbiome, findings in the first pilot studies in GPA, and will discuss future strategies. CrownEntities:
Keywords: ANCA; GPA; Microbiome; Staphylococcus aureus; Vasculitis
Year: 2020 PMID: 33489010 PMCID: PMC7804347 DOI: 10.1016/j.csbj.2020.12.031
Source DB: PubMed Journal: Comput Struct Biotechnol J ISSN: 2001-0370 Impact factor: 7.271
Summary of three independent studies of the nasal microbiome in patients with GPA. Geographical differences, differences in disease activity status (especially in the ENT tract), treatment differences (i.e., antibiotics), storage, and analysis paths limit comparability of results.
| Rhee et al. | Lamprecht et al. | Wagner et al. | |
|---|---|---|---|
| GPA patients (number) | 60 | 29 | 56 |
| Country | USA | Germany | UK |
| ANCA type | PR3 (60%), MPO (25%), negative (15%) | PR3 (83%), MPO (3%), negative (14%) | Not reported |
| New diagnosis | 5 (8%) | 0% | Not reported |
| Disease status | Remission (75%), severe flare (3%), limited flare (17%), persistent disease (5%) | Remission (79%), active disease (21%) | Remission (79%), active disease (21%) |
| Current ENT disease activity | 10% | 21% | 21% |
| Antibiotic treatment | 48% (in the past 6 months) | No recent prescription | 17.9% (in the past months) |
| Storage | Freezer (swab; −80 °C) | Immediately processed (swab) | Immediately processed (swab) |
| Main findings | GPA patients had a lower relative abundance of | GPA patients had an increase in bacterial species assigned to the families | 16S: GPA patients (grouped together) had a distinct microbiome composition compared to healthy controls WGSS: active GPA group was different to the healthy and diseased controls |
| No difference in the relative abundance of | Culture: | ||
| Strengths | Additional analysis of the fungal community composition; investigations focusing on non-immunosuppression users versus patients on immunosuppression; well characterized patients | Comparison of GPA patients with a diseased comparison group (RA); in depth analyses of the bacterial community composition; the use of UMERS as a novel method that can detect distantly related microorganisms; well characterized patients | First study to perform whole genome shotgun sequencing from nasal swabs including study of critical pathways involved; report of significant findings with higher relative abundance; well characterized patients; Remission patients as comparators |
| Limitations | Cross-sectional; small sample size; no immediate processing of samples; no information on current smoking status, patients on immunosuppression (>50%) and antibiotics (25%) at the time of nasal swab | Cross-sectional, small sample size, patients on immunosuppression (28/29 on steroids; and a majority on additional measures) | Cross-sectional; small sample size; no information on current smoking status, steroid prescription (75% active group, 47.6% remission group), additional immunosuppression (75% active group, 57.1% inactive group) |
Abbreviations used: ANCA (anti-neutrophil cytoplasmic antibody), ENT (ear, nose and throat), GPA (granulomatosis with polyangiitis), MPO (myeloperoxidase), PR3 (proteinase 3), RA (rheumatoid arthritis), UK (United Kingdom), USA (United States of America), WGSS (whole genome shotgun sequencing).
Overlapping and stand-alone recommendations/guidelines have been issued to control for several lines of contamination. Importantly, studies should include negative and positive controls which help to identify batch effects and contamination between different suppliers of DNA extraction kits. Results should be critically discussed in terms of ecological plausibility. Sample time points and essential confounders such as the use of antibiotics within a time period of a few weeks before sampling need to be recorded. Uniform sample collection and processing (i.e., storage) are necessary to guarantee reproducibility of the results. The validity of the results is increased when a separate discovery and validation cohorts are recruited.
| Use all available lines of defense |
Fig. 1The figure (1.1.) was provided by courtesy of Encyclopaedia Britannica, Inc.